Dipivefrin is a prodrug of epinephrine used in ophthalmic solutions to reduce intraocular pressure in chronic open-angle glaucoma. It is available as ophthalmic solution (eye drops).
- Mechanism
- Curator reviewed
Dipivefrin is a prodrug with little or no pharmacologically activity until it is hydrolyzed into epinephrine inside the human eye. The liberated epinephrine, an adrenergic agonist, appears to exert its action by stimulating α -and/or β2-adrenergic receptors, leading to a decrease in aqueous production and an enhancement of outflow facility. The dipivefrin prodrug delivery system is a more efficient way of delivering the therapeutic effects of epinephrine, with fewer side effects than are associated with conventional epinephrine therapy.
- Primary indication
- Dipivefrin is a prodrug which is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.Curator reviewed · 1 structured indication
- Formula / weight
- C19H29NO5 · 351.4373 g/mol (avg)
- First approval
- Canada, 1998 · United States, 1994
- Also known as
- Dipivalyl epinephrine · Dipivefrine
- Code names
- DPE · K 30081
Resolves to
OCUJLLGVOUDECM-UHFFFAOYSA-NSMILESCNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1What you can answer from here — as of October 01, 2026
Which drugs share a target with Dipivefrin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account